EXTON, Pa.--(BUSINESS WIRE)--Jan. 30, 2006--Adolor Corporation (NASDAQ:ADLR) announced today that the U.S. Food and Drug Administration (FDA) has placed the Investigational New Drug Application (IND) for ADL5859, a novel, oral compound that targets the Delta opioid receptor, on clinical hold pending additional preclinical safety studies and additional information regarding the Company's proposed Phase 1 protocol. Until this data is compiled and submitted, the Company will be unable to initiate human clinical trials on this compound. Adolor filed the IND with the FDA on December 29, 2005.
